|
|
News Breaks
|
October 22, 2009
|
| 16:32 EDT |  | SGEN |
| theflyonthewall.com: | Seattle Genetics updates pipeline progress | | “We achieved several significant milestones during the third quarter, including completing enrollment in the pivotal clinical trial of brentuximab vedotin, our lead antibody-drug conjugate for Hodgkin lymphoma,” said Clay B. Siegall, Ph.D., President and CEO of Seattle Genetics. “We expect data from the pivotal trial in the second half of 2010, and are continuing to position the program for a planned U.S. product launch in the second half of 2011, assuming priority review of our marketing application. During the third quarter, we also submitted an investigational new drug application for our next proprietary ADC, SGN-75, and two more of our ADC collaborators initiated clinical trials with programs using our technology. In addition, we received net proceeds of $128M from a public offering that further strengthened our financial position. We anticipate achieving multiple milestones across our pipeline over the remainder of 2009 and in 2010.” :theflyonthewall.com |
|
|
News For SGEN From The Last 14 Days Check below for free stories on SGEN the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 13, 2012
|
| 16:11 EDT | | SGEN |
| | 16:09 EDT |  | SGEN |
| theflyonthewall.com: | Seattle Genetics sees 2012 revenue from collaboration, licenses $55M-$65M | | Seattle Genetics anticipates that revenues from collaboration and license agreements in 2012 will be in the range of $55M-$65M. The company said it is not providing guidance on expected revenue from ADCETRIS product sales at this time. :theflyonthewall.com |
| | 16:07 EDT | | SGEN |
|
|
|
|
|
Subscribe for More Information